Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.
Selection and design of high-affinity RNA ligands for HIV-1 Rev.
Gene. 1993 Dec 27;137(1):19-24. Unique Identifier : AIDSLINE MED/94109690 Giver L; Bartel DP; Zapp ML; Green MR; Ellington AD; Department of Chemistry, Indiana University, Bloomington 47405.
Abstract:
We have used in vitro selection to isolate minimal, high-affinity RNA ligands for the Rev protein of HIV-1. Sequence analysis reveals that the tightest binding aptamers exhibit some similarity to a Rev-binding element (RBE) localized within the Rev-responsive element (RRE), but also contain novel sequence and structural motifs. A short helical stem and bulged nucleotides (nt) CUC ... UYGAG that have no counterpart in the wild-type (wt) element contribute to high-affinity binding. We have designed and synthesized a short (37 nt) RNA molecule that incorporates this motif; this RNA ligand has from three- to fivefold tighter binding than the full-length wt element, and up to 16-fold tighter than minimal wt RBEs. A guanosine:guanosine pairing that is postulated to occur in the wt element has been altered to other base pairings in the context of our optimized minimal element. RNAs that contain non-Watson-Crick base pairings, that can be modeled as isosteric to the wt G:G pair, bind Rev up to 160-fold tighter than elements that contain canonical Watson-Crick pairings or non-isosteric mismatches. These results support the hypothesis that Rev recognizes structural features associated with a non-Watson-Crick base pair.
Keywords: Base Composition Base Sequence Gene Products, rev/*CHEMISTRY Ligands Models, Chemical Molecular Sequence Data Nucleic Acid Conformation Protein Binding RNA/*CHEMICAL SYNTHESIS JOURNAL ARTICLE 940430
M9440027
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.